Top

Published in:

01-10-2010 | Original paper

Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk

Authors: Galina Lurie, Kathryn L. Terry, Lynne R. Wilkens, Pamela J. Thompson, Katharine E. McDuffie, Michael E. Carney, Rachel T. Palmieri, Daniel W. Cramer, Marc T. Goodman

Published in: Cancer Causes & Control | Issue 10/2010

Abstract

Inflammation is postulated to play an important role in ovarian carcinogenesis. Prostaglandin endoperoxide synthase 2 (PTGS2) is responsible for the conversion of arachidonic acid to prostaglandins in response to inflammation. In a pooled analysis of two population-based studies, the Hawaii Ovarian Cancer Case–Control Study and the New England Case–Control Study, including 1,025 women with invasive ovarian carcinoma and 1,687 cancer-free controls, the association of ovarian cancer risk with the PTGS2 rs5275 polymorphism and the use of nonsteroidal antiinflammatory drugs (NSAIDs) were examined. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression. In the pooled analysis, the CC genotype was associated with a reduced risk of nonserous ovarian carcinoma (OR = 0.66; CI: 0.44–0.98). In addition, the lowest risk was observed among carriers of the CC genotype who were users of only nonaspirin NSAIDs (OR = 0.43; CI:0.20–0.93) in all women combined. The association of PTGS2 rs5275 with nonserous ovarian carcinoma and possible effect modification by NSAID use needs further validation, preferably in prospective studies.

Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288CrossRefPubMed

Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2(7716):163CrossRefPubMed

Espey LL (1994) Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 50(2):233–238CrossRefPubMed

Richards JS, Russell DL, Ochsner S, Espey LL (2002) Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 64:69–92CrossRefPubMed

Ames BN, Shigenaga MK, Hagen TM (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 90(17):7915–7922CrossRefPubMed

Hofseth LJ, Ying L (2006) Identifying and defusing weapons of mass inflammation in carcinogenesis. Biochim Biophys Acta 1765(1):74–84PubMed

Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A (2006) Analgesic drug use and risk of ovarian cancer. Epidemiology 17(1):104–107CrossRefPubMed

Prizment AE, Folsom AR, Anderson KE (2010) Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 19(2):435–442CrossRefPubMed

Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani A, Trichopoulos D (1993) Hair dyes, analgesics, tranquilizers and perineal talc application as risk factors for ovarian cancer. Int J Cancer 55(3):408–410CrossRefPubMed

10.

Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER (1998) Over-the-counter analgesics and risk of ovarian cancer. Lancet 351(9096):104–107CrossRefPubMed

11.

Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE (2001) Aspirin and epithelial ovarian cancer. Prev Med 33(6):682–687CrossRefPubMed

12.

Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C (2004) Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 108(2):281–286CrossRefPubMed

13.

Tavani A, Gallus S, La VC, Conti E, Montella M, Franceschi S (2000) Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 11(9):1171–1173CrossRefPubMed

14.

Hannibal CG, Rossing MA, Wicklund KG, Cushing-Haugen KL (2008) Analgesic drug use and risk of epithelial ovarian cancer. Am J Epidemiol 167(12):1430–1437CrossRefPubMed

15.

Pinheiro SP, Tworoger SS, Cramer DW, Rosner BA, Hankinson SE (2009) Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 169(11):1378–1387CrossRefPubMed

16.

Crew KD, Neugut AI (2006) Aspirin and NSAIDs: effects in breast and ovarian cancers. Curr Opin Obstet Gynecol 18(1):71–75CrossRefPubMed

17.

Smith WL, Garavito RM, DeWitt DL (1996) Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271(52):33157–33160CrossRefPubMed

18.

DuBois RN, Abramson SB, Crofford L et al (1998) Cyclooxygenase in biology and disease. FASEB J 12(12):1063–1073PubMed

19.

Landen CN Jr, Mathur SP, Richardson MS, Creasman WT (2003) Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 188(5):1174–1176CrossRefPubMed

20.

Shigemasa K, Tian X, Gu L, Shiroyama Y, Nagai N, Ohama K (2003) Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 22(1):99–105PubMed

21.

Khalifeh I, Munkarah AR, Lonardo F et al (2004) Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol 23(2):162–169CrossRefPubMed

22.

Li S, Miner K, Fannin R, Carl BJ, Davis BJ (2004) Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol 92(2):622–627CrossRefPubMed

23.

Cok SJ, Morrison AR (2001) The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 276(25):23179–23185CrossRefPubMed

24.

Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM (2000) Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 275(16):11750–11757CrossRefPubMed

25.

Yang H, Gu J, Lin X et al (2008) Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. Clin Cancer Res 14(7):2236–2244CrossRefPubMed

26.

Cho KR, Shih I (2009) Ovarian cancer. Annu Rev Pathol 4:287–313CrossRefPubMed

27.

Mok SC, Kwong J, Welch WR et al (2007) Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5–6):367–376PubMed

28.

Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I (2009) Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 14(5):383–391CrossRefPubMed

29.

Chiaffarino F, Parazzini F, Bosetti C et al (2007) Risk factors for ovarian cancer histotypes. Eur J Cancer 43(7):1208–1213CrossRefPubMed

30.

Gates MA, Rosner BA, Hecht JL, Tworoger SS (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171(1):45–53CrossRefPubMed

31.

Berchuck A, Schildkraut JM, Pearce CL, Chenevix-Trench G, Pharoah PD (2008) Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium. Adv Exp Med Biol 622:53–67CrossRefPubMed

32.

Terry KL, De VI, Titus-Ernstoff L, Shih MC, Cramer DW (2005) Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 65(13):5974–5981CrossRefPubMed

33.

Tung KH, Goodman MT, Wu AH et al (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629–638CrossRefPubMed

34.

Backlund MG, Mann JR, DuBois RN (2005) Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 69(Suppl 1):28–32CrossRefPubMed

35.

Thun MJ (2000) Beyond willow bark: aspirin in the prevention of chronic disease. Epidemiology 11(4):371–374CrossRefPubMed

36.

Cook NR, Lee IM, Gaziano JM et al (2005) Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 294(1):47–55CrossRefPubMed

37.

Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101(10):1206–1218PubMed

38.

Cuzick J, Otto F, Baron JA et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507CrossRefPubMed

39.

Potter JD (1999) Colorectal cancer: molecules and populations. J Natl Cancer Inst 91(11):916–932CrossRefPubMed

40.

Denkert C, Kobel M, Pest S et al (2002) Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160(3):893–903PubMed

41.

Munkarah A, Ali-Fehmi R (2005) COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 17(1):49–53PubMed

42.

Ozel E, Pestereli HE, Simsek T, Erdogan G, Karaveli FS (2006) Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters? Int J Gynecol Cancer 16(2):549–555CrossRefPubMed

43.

Uddin S, Ahmed M, Hussain A et al (2010) Cyclooxygenase-2 inhibition inhibits PI3 K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 126(2):382–394CrossRefPubMed

44.

Seo SS, Song YS, Kang DH et al (2004) Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 92(3):927–935CrossRefPubMed

Title: Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk
Authors: Galina Lurie
Kathryn L. Terry
Lynne R. Wilkens
Pamela J. Thompson
Katharine E. McDuffie
Michael E. Carney
Rachel T. Palmieri
Daniel W. Cramer
Marc T. Goodman
Publication date: 01-10-2010
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 10/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9602-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2010

Racial/ethnic and socioeconomic disparities in mortality among women diagnosed with cervical cancer in New York City, 1995–2006

Evaluating the impact of an educational intervention to increase CRC screening rates in the African American community: a preliminary study

Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups?

A remarkable reduction of breast cancer deaths in screened versus unscreened women: a case-referent study

Polymorphisms in one-carbon metabolism pathway genes, urinary arsenic profile, and urothelial carcinoma

Vitamin and mineral use and risk of prostate cancer: misleading?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer